Trulicity

Prescription medicine

GLP-1 receptor agonist; injectable for type 2 diabetes

FDA‑approved prescription medicine
EU marketing authorisation via EMA (active substance dulaglutide) as per EMA EPAR for Trulicity. :contentReference[oaicite:25]{index=25}

FDA‑approved prescription medicine
EU marketing authorisation via EMA (active substance dulaglutide) as per EMA EPAR for Trulicity. :contentReference[oaicite:25]{index=25}

GLP-1 receptor agonist; injectable for type 2 diabetes

Description

Trulicity (dulaglutide) is a once‑weekly injectable medicine used in adults and children 10 years or older with type 2 diabetes to improve glycemic control. It is also indicated in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors to reduce the risk of major adverse cardiovascular events (such as heart attack, stroke, or death). The active substance is dulaglutide, a GLP-1 receptor agonist, which stimulates insulin release in response to meals, suppresses inappropriate glucagon secretion, slows gastric emptying, and reduces appetite. The solution is provided in a prefilled single‑use pen for subcutaneous injection. :contentReference[oaicite:0]{index=0}

Bnefits

Improves blood sugar (glucose) control in type 2 diabetes as an adjunct to diet and exercise. :contentReference[oaicite:1]{index=1}
Reduces risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. :contentReference[oaicite:2]{index=2}
Convenient once‑weekly dosing via prefilled injection pen — no mixing, measuring or needle handling required. :contentReference[oaicite:3]{index=3}

Indications

Adjunct to diet and exercise to improve glycemic control in adults and children 10 years and older with type 2 diabetes mellitus. :contentReference[oaicite:4]{index=4}
To reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors. :contentReference[oaicite:5]{index=5}

Composition

Active ingredient: dulaglutide. :contentReference[oaicite:6]{index=6}
Inactive ingredients: citric acid anhydrous, mannitol, polysorbate 80, trisodium citrate dihydrate, in water for injection. :contentReference[oaicite:7]{index=7}

Formulation

Sterile, preservative-free solution for subcutaneous injection, supplied in a single-dose prefilled pen. :contentReference[oaicite:8]{index=8}
Available strengths: 0.75 mg, 1.5 mg, 3 mg, or 4.5 mg per 0.5 mL injection. :contentReference[oaicite:9]{index=9}

Packaging

Prefilled single‑dose injection pen containing 0.5 mL solution of dulaglutide at various strengths (0.75, 1.5, 3.0, 4.5 mg). :contentReference[oaicite:10]{index=10}

Usage

Inject subcutaneously once weekly in the abdomen, thigh or upper arm. Injection may be done any time of day, with or without meals. :contentReference[oaicite:11]{index=11}
Start with 0.75 mg once weekly; after at least 4 weeks, may be increased to 1.5 mg once weekly if additional glycemic control is needed. Further dose escalation in 1.5 mg increments not before 4 weeks, up to a maximum of 4.5 mg once weekly. :contentReference[oaicite:12]{index=12}
Use exactly as prescribed by a healthcare provider; do not share pens, syringes, or needles with others. :contentReference[oaicite:13]{index=13}

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC). :contentReference[oaicite:15]{index=15}
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). :contentReference[oaicite:16]{index=16}
Known hypersensitivity to dulaglutide or any of the excipients. :contentReference[oaicite:17]{index=17}
Not recommended for patients with severe gastrointestinal disease (e.g., severe gastroparesis). :contentReference[oaicite:18]{index=18}

Adverse Effects

Nausea. :contentReference[oaicite:19]{index=19}
Diarrhea. :contentReference[oaicite:20]{index=20}
Vomiting. :contentReference[oaicite:21]{index=21}
Abdominal (stomach) pain. :contentReference[oaicite:22]{index=22}
Decreased appetite. :contentReference[oaicite:23]{index=23}
Possible serious side effects: risk of thyroid C‑cell tumors (thyroid cancer observed in rodent studies), pancreatitis, acute kidney injury (especially with dehydration), serious allergic reactions, and possible gastrointestinal issues. :contentReference[oaicite:24]{index=24}

Storage Conditions

Not publicly listed

Duration

Long-term, as directed by prescribing physician; duration depends on glycemic control goals and cardiovascular risk. Not fixed. :contentReference[oaicite:14]{index=14}